Pharmacokinetic Profile of a Novel Sustained-Release Caffeine with Extended Benefits on Alertness and Mood: A Randomized, Double-Blind, Single-Dose, Active-Controlled, Crossover Study

•Xtenergy™ demonstrated a slow absorption and sustained plasma caffeine levels based on Tmax, t1/2 and AUC data.•Tmax was 325.53% higher (p < 0.05) and t1/2 was 21.34% higher (p < 0.05) for Xtenergy™ as compared to immediate release caffeine.•Xtenergy™ demonstrated similar total exposure as IRC based on the 90% CI of 84.63% - 114.45% for AUC0–24.•Slow-Release caffeine showed significant beneficial effects (p < 0.05) at several of the time points on alertness, tiredness, overall mood, jitteriness and less tenseness without any safety issues.